Brand Insights - Thought Leadership | Paid Program | BioPharm Communications
How non-endemic platforms can help brand teams amplify their use of KOLs in HCP outreach
The Importance of Opinion Leader-Content in a Digital Transformation
Published: | Updated:
Marketers are working to reimagine how they leverage key opinion leader (KOL) support during COVID-19.
The Non-Personal Promotion Equation
Published: | Updated:
Non-personal promotion is a foundational component of most brands’ omnichannel marketing strategy.
Marketing to HCPs in the New World Order
ByNorm Phillips, Brand Insights Contributor, EVP and Chief Marketing Officer, BioPharm Communications
Published: | Updated:
The current COVID-19 pandemic has taken the world of HCP marketing and turned it upside down. Biopharma has had to make instantaneous decisions on how to market in this new environment, who to market to, which tactics to significantly increase, and which tactics to walk away from-all with no historical playbook.
Minimizing the Negative Impact of Sales Rep Vacancies
Published: | Updated:
The impact of vacant sales territories on overall brand performance is often underestimated within pharma and biotech companies.
Successful Integration of First- and Third-Party HCP Promotion
ByNorm Phillips, Brand Insights Contributor, EVP and Chief Marketing Officer, BioPharm Communications
Published: | Updated:
Pharma and biotech marketers are facing more challenges than ever in communicating brand messages to target healthcare professionals (HCPs).
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: FDA Approves Hernexeos
2
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
3
FDA Approves Hernexeos Under National Priority Voucher Program
4
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children
5